Founded in 2014, the company is located in the National Innovation Talent Cultivation Demonstration Base of Hi-Tech Park, Jiangning District, Nanjing, with a laboratory area of nearly 2,000 square meters, and is a company dedicated to the research and development of innovative drugs and high-end generics. The company's innovative drug R&D focuses on liver diseases, cancer treatment and autoimmune diseases; generic drug R&D mainly practices the system of marketing authorization holder (MAH), and has a quality management system for the whole life cycle of drugs. The company's core strategy is technology and innovation, with self-developed formulation technology platform and innovative drug R&D platform, and drug R&D based on the technology platform, constantly enriching the company's product line. The company's formulation technology platform owns skeleton tablet slow release technology, micro-pill slow and controlled release technology, Lipodose technology and innovative drug development technology.
-
R&D direction selection
-
R&D support
-
R&D strategy